Trulicity Cost in Idaho 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Trulicity Cost in Idaho Right Now?

The Eli Lilly manufacturer list price for Trulicity is $931 per month across Idaho retail pharmacies in 2026, regardless of dose. That figure applies to all four available strengths: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg weekly auto-injector pens. Cash-pay patients at chains such as Walmart, Walgreens, or Smith's Food and Drug in Boise, Nampa, or Idaho Falls will see pricing clustered near that list price without a discount program or insurance adjudication.

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA approved it in September 2014 under NDA 125469 for glycemic control in adults with type 2 diabetes, and later expanded labeling covers cardiovascular risk reduction in adults with established cardiovascular disease or multiple risk factors [1]. The drug is delivered as a single-dose pen prefilled with 0.5 mL solution. Patients self-inject once weekly on a consistent day, with or without food [2].

Because no generic dulaglutide exists in the United States as of mid-2025, Idaho patients cannot substitute a cheaper bioequivalent at the pharmacy counter. The FDA has not approved any generic or biosimilar dulaglutide. That single fact keeps cash prices anchored near list price for uninsured or underinsured residents statewide.

For context, the REWIND cardiovascular outcomes trial (N=9,901) showed dulaglutide 1.5 mg weekly reduced the composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death by 12% relative to placebo over a median 5.4 years (HR 0.88; 95% CI 0.79, 0.99; P=0.026) [3]. That evidence base is one reason prescribers in Idaho and nationwide continue writing dulaglutide scripts despite the high cost.

Does Idaho Medicaid Cover Trulicity?

Idaho Medicaid does not currently cover Trulicity for type 2 diabetes. Idaho's Medicaid preferred drug list (PDL) as of 2026 does not include dulaglutide as a covered GLP-1 agonist for standard type 2 diabetes management, meaning prior authorization requests will be denied at the formulary level for most beneficiaries [4].

This creates a real access gap. Idaho had approximately 327,000 Medicaid enrollees as of early 2025 per CMS data, and roughly 11.3% of Idaho adults carry a type 2 diabetes diagnosis according to CDC surveillance [5]. Patients who rely on Idaho Medicaid and need a GLP-1 agonist should ask their prescriber about alternatives that are covered, such as oral semaglutide (Rybelsus) or liraglutide (Victoza), depending on current PDL status. Formulary status changes quarterly, so patients should verify current coverage directly with Idaho Department of Health and Welfare at enroll.dhw.idaho.gov.

Medicaid coverage for cardiovascular indications or obesity management under Medicaid expansion may differ. A prescriber who documents cardiovascular disease as the primary indication rather than glycemic control alone could attempt a medical necessity appeal citing the REWIND data [3], though approval is not guaranteed and Idaho's Medicaid program retains broad formulary authority.

Which Private Insurance Plans Cover Trulicity in Idaho?

Most commercial plans available through Idaho's Your Health Idaho marketplace cover Trulicity on Tier 3 or Tier 4, producing typical member cost-sharing between $60 and $150 per month after deductible, depending on the plan [6]. Large employer-sponsored plans, which cover most working-age Idaho residents, generally include dulaglutide on specialty tiers with similar cost-sharing ranges.

Blue Cross of Idaho, Regence BlueShield of Idaho, and SelectHealth each offer qualified health plans in Idaho. Specific formulary placement changes annually. Patients should log into their insurer's drug lookup tool or call member services before the January coverage year begins to confirm tier status and any step-therapy requirements. Many plans require documented failure of metformin, or sometimes a sulfonylurea, before approving a GLP-1 agonist.

Prior authorization criteria commonly require [7]:

• A confirmed type 2 diabetes diagnosis (not type 1)
• HbA1c at or above a threshold (frequently 7.5% or 8.0%)
• Current or recent use of metformin at maximum tolerated dose
• Prescriber attestation that the patient has been counseled on lifestyle modification

Meeting all four criteria in the initial PA submission shortens approval timelines substantially.

How the Eli Lilly Savings Card Works in Idaho

Eli Lilly's Trulicity savings card (formally the Lilly Cares program and the commercial co-pay card) can reduce monthly out-of-pocket cost to as low as $25 for eligible commercially insured Idaho patients [8]. The card does not work for patients covered by any federal or state government insurance, including Medicare Part D, Idaho Medicaid, TRICARE, or any other government-funded program. That exclusion is federal law, not a Lilly policy choice.

Eligible patients can enroll at TrulicityHCP.com or through their prescriber's office. The card activates at the pharmacy and covers the gap between insurance adjudication and the $25 cap, up to a defined annual maximum benefit. In 2025, Lilly set that cap at $150 per month in co-pay coverage for most commercially insured patients.

For uninsured patients, Lilly's separate Insulin Value Program does not apply to Trulicity. However, the Lilly Cares Foundation patient assistance program provides Trulicity at no cost to qualifying uninsured or underinsured patients with household income at or below 400% of the federal poverty level [8]. Idaho residents apply directly through LillyCares.com or by calling 1-800-545-5979.

Is Compounded Dulaglutide Legal in Idaho?

Compounded dulaglutide from a state-licensed 503A pharmacy operating in Idaho is legal as of mid-2025. 503A pharmacies compound medications for individual patients under a valid prescription from a licensed prescriber [9]. They operate under Idaho Board of Pharmacy rules and federal FDCA Section 503A exemptions.

This is a nuanced area. The FDA placed semaglutide on the drug shortage list in 2022, allowing 503B outsourcing facilities to compound it at scale. Dulaglutide has not appeared on the FDA drug shortage list in the same manner, which means 503B bulk compounding of dulaglutide is on shakier legal ground. 503A compounding for individual patients, however, proceeds under different statutory authority and is not dependent on shortage status [9].

Idaho Board of Pharmacy Rule IDAPA 27.01.01 governs compounding pharmacies operating within the state. A licensed 503A pharmacy in Boise or operating via mail-order into Idaho can compound dulaglutide for a specific patient under a valid prescription. The patient should confirm the pharmacy holds a current Idaho pharmacy license and that the prescribing clinician has conducted a proper patient evaluation [10].

Cost for compounded dulaglutide varies by pharmacy and by concentration, but prices frequently range from $150 to $350 per month depending on dose and formulation, substantially below the $931 Lilly list price. Some telehealth practices bundle the compounded medication with a monthly membership fee. Idaho patients should request an itemized cost breakdown before enrolling.

HealthRX 4-Step Cost-Minimization Decision Framework for Idaho Trulicity Patients

1. Check insurance first. Log into your plan's formulary tool and confirm tier, PA requirements, and step-therapy rules before assuming cash-pay is necessary.
2. If commercially insured and under 65, apply for the Lilly savings card at TrulicityHCP.com to cap your co-pay at $25 per month.
3. If uninsured or on Idaho Medicaid, apply to the Lilly Cares Foundation (LillyCares.com) for the patient assistance program. Processing takes 2 to 4 weeks.
4. If ineligible for assistance programs and cash-pay prices are prohibitive, ask your prescriber whether compounded dulaglutide from a licensed Idaho 503A pharmacy is clinically appropriate for your situation.

Can You Get a Trulicity Prescription via Telehealth in Idaho?

Yes. Idaho allows telehealth prescribing of Schedule V and non-controlled prescription medications, and dulaglutide is a non-controlled substance. A licensed prescriber holding an Idaho medical license can conduct a synchronous audio-video visit with an Idaho-resident patient and issue a valid dulaglutide prescription at the conclusion of that visit [11].

The Idaho Telehealth Access Act, codified at Idaho Code Section 54-5701, affirms that telehealth services are subject to the same standard of care as in-person services. Prescribers must still perform an adequate clinical evaluation, review relevant labs (typically HbA1c, kidney function, and a contraindication screen for personal or family history of medullary thyroid carcinoma or MEN2 syndrome), and document clinical decision-making in the patient record [11].

Practically, this means Idaho patients in rural counties such as Custer, Lemhi, or Clark, where endocrinologists are scarce, can access dulaglutide through telehealth platforms including HealthRX without traveling to Boise or Twin Falls. The prescription can be routed to a local pharmacy or, where applicable, to a licensed compounding pharmacy that ships within Idaho.

Telehealth prescribing does not bypass insurance prior authorization. The PA process runs through the patient's insurer regardless of how the prescription was generated.

GLP-1 Clinical Evidence Supporting Trulicity Use

The clinical case for dulaglutide extends well beyond glycemic lowering. The REWIND trial enrolled 9,901 adults with type 2 diabetes aged 50 and older, at least 31% of whom had no prior cardiovascular event at baseline, making it one of the most primary-prevention-inclusive CVOT populations among GLP-1 trials [3]. Dulaglutide 1.5 mg weekly reduced the primary MACE endpoint at a median 5.4-year follow-up with a number needed to treat of approximately 69 patients to prevent one MACE event.

Glycemic data from the AWARD trial series are also relevant for prescribers weighing dose selection. AWARD-11 (N=1,842) demonstrated that the 3 mg and 4.5 mg doses of dulaglutide produced statistically greater HbA1c reductions than the 1.5 mg dose, with 3 mg yielding a mean HbA1c reduction of 1.6% and 4.5 mg yielding 1.8% from a baseline of approximately 8.6% [12]. Body weight reduction at 4.5 mg reached a mean of 4.7 kg at 52 weeks [12].

The American Diabetes Association's 2024 Standards of Care in Diabetes recommend GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes and established cardiovascular disease, high cardiovascular risk, chronic kidney disease, or obesity, independent of baseline HbA1c [13]. That recommendation applies directly to the Idaho patient population, where obesity prevalence reached 31.2% among adults in 2023 per CDC BRFSS data [5].

The FDA label for dulaglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies [1]. Prescribers must screen patients for personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 before initiating therapy. Patients with either contraindication should not receive dulaglutide.

Comparing Trulicity to Other GLP-1 Options Available in Idaho

Dulaglutide is not the only GLP-1 agonist available to Idaho patients, and cost comparison across agents matters for patients navigating coverage decisions.

Semaglutide (Ozempic) 1 mg weekly carries a similar list price near $900 per month and shares the GLP-1 receptor agonist mechanism. The SUSTAIN-6 trial (N=3,297) demonstrated cardiovascular benefit with semaglutide in a higher-risk population [14]. Ozempic's formulary placement on Idaho commercial plans differs by insurer, so one agent may be preferred over the other depending on a patient's specific plan.

Liraglutide (Victoza) is older, dosed daily rather than weekly, and may carry lower list pricing at some Idaho pharmacies. The LEADER trial (N=9,340) established its cardiovascular benefit [15]. Weekly dosing with dulaglutide or semaglutide generally produces better adherence than daily liraglutide in real-world studies [16].

Exenatide extended-release (Bydureon BCise) provides another once-weekly option. It does not have the same cardiovascular outcomes trial data as dulaglutide or semaglutide, and its use has declined since those CVOT results were published.

For Idaho patients whose prescriber recommends a GLP-1 agonist but for whom Trulicity is unaffordable, the clinical conversation should include all three alternatives and their respective formulary positions on the patient's specific insurance plan.

What to Bring to Your Prescriber Appointment in Idaho

Patients in Idaho who want to discuss Trulicity with a prescriber, whether in person or via telehealth, should bring or have available:

• Most recent HbA1c result (within 6 months is preferred; within 12 months is minimally acceptable)
• Current medication list including over-the-counter supplements
• Insurance card and knowledge of your pharmacy benefit tier structure
• Documentation of any prior GLP-1 trial, if applicable, including reason for discontinuation
• Personal and first-degree family history of thyroid cancer or MEN2

A recent eGFR or serum creatinine is also useful. Dulaglutide does not require dose adjustment for renal impairment and has been studied down to eGFR 15 mL/min/1.73m2, but the prescriber may want baseline kidney function on file [2].

Nausea is the most common adverse effect, occurring in approximately 12 to 13% of patients in the 0.75 mg group and rising to about 21% at 4.5 mg in AWARD-11 [12]. Starting at 0.75 mg weekly for four weeks before uptitrating to 1.5 mg reduces early gastrointestinal side effects for most patients.

GoodRx, NeedyMeds, and Other Discount Tools in Idaho

GoodRx coupons for Trulicity at Idaho pharmacies typically save between 5% and 15% off the list price, landing most patients in the $800 to $890 range for a monthly supply. That discount is real but modest. GoodRx pricing is not combinable with insurance, so patients with even a basic commercial plan will usually find their insurance adjudication produces a lower out-of-pocket cost than GoodRx [17].

NeedyMeds.org lists patient assistance programs by drug name. Searching "dulaglutide" on that site returns the Lilly Cares Foundation program as the primary option, consistent with what the manufacturer offers directly [18].

RxSaver and Blink Health operate similarly to GoodRx in Idaho. None of these tools combine with insurance or with Lilly's co-pay card. The hierarchy of savings tools for most Idaho patients is: insurance co-pay card first, Lilly savings card second, and GoodRx or similar third.

Mark Kromer, Pharm.D., clinical pharmacist and HealthRX formulary analyst, notes: "In Idaho, the single most underused savings tool for commercially insured Trulicity patients is the Lilly co-pay card. Fewer than half of eligible patients activate it at the pharmacy, leaving $100 or more per month on the table."